EUVIMEDEUVIMED entdecken
Crossref

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis

Sara Gandini iD, Aliana Guerrieri-Gonzaga iD, Davide Serrano iD, Roberta Rizzo iD, Matteo Lazzeroni iD, Matteo Puntoni iD, Tania Buttiron Webber, Gaetano Aurilio, Harriet Johansson, Alessio Carbone iD, Livia Giordano, Maria Digennaro und 11 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-26-00841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Sara Gandini und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Tamoxifen 20 mg once-daily reduces the risk of breast cancer recurrence after ductal carcinoma in situ (DCIS), but its use is limited by adverse effects. Lower doses may be effective, but benefit durability and differences according to menopausal status and site of recurrence remain uncertain. METHODS We conducted an individual-participant pooled analysis of three clinical studies involving women with estrogen receptor–positive or unknown DCIS, microinvasive carcinoma, or high-risk breast lesions. Participants received low-dose tamoxifen (5 mg once daily or 10 mg once-every other day for 2-5 years) or a control intervention. The primary end point was breast cancer–free interval, defined as the first occurrence of any ipsilateral or contralateral invasive breast cancer, DCIS, regional recurrence, or distant recurrence. Hazard ratios (HRs) were estimated with mixed-effects Cox models accounting for between-study variability. RESULTS Among 1,545 women included with a median follow-up of 9.4 years, low-dose tamoxifen reduced breast cancer events overall, with evidence of treatment heterogeneity according to menopausal status ( P = .01). In postmenopausal women, breast cancer events occurred in 40 of 335 receiving low-dose tamoxifen versus 93 of 401 controls (HR, 0.51 [95% CI, 0.35 to 0.73]), with a 10-year absolute reduction of 11.2%. Among premenopausal women, no significant reduction was observed (HR, 0.90 [95% CI, 0.70 to 1.17]), although contralateral breast cancer was reduced (HR, 0.45 [95% CI, 0.26 to 0.76]). Serious adverse events were infrequent and similar between groups. CONCLUSION Low-dose tamoxifen was associated with a sustained reduction in breast cancer events, with differences by menopausal status and site of event. These findings support endocrine dose de-escalation to improve the benefit-risk profile of preventive therapy in DCIS and high-risk lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingAntineoplastic Agents, HormonalHumansFemaleMiddle AgedAgedAdultNeoplasm Recurrence, Local

Substanzen

TamoxifenAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
  • Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy.
  • Medical Oncology Unit, EO Ospedali Galliera, Genoa, Italy.
  • CPO-Piedmont-AOU Città della Salute e della Scienza, Turin, Italy.
  • IRCCS, Istituto Tumori "Giovanni Paolo II", Bari, Italy.

ORCID-Profile: Sara Gandini, Aliana Guerrieri-Gonzaga, Davide Serrano, Roberta Rizzo, Matteo Lazzeroni, Matteo Puntoni, Alessio Carbone, Laura Cortesi, Francesco Millo, Patrizia Serra, Berta Sousa, Pedro Gouveia, Bernardo Bonanni, Andrea DeCensi

Zitieren

APA

Gandini, S., Guerrieri-Gonzaga, A., Serrano, D., Rizzo, R., Lazzeroni, M., Puntoni, M., Buttiron Webber, T., Aurilio, G., Johansson, H., Carbone, A., Giordano, L., Digennaro, M., Cortesi, L., Millo, F., Cagossi, K., Aprile, G., Serra, P., Gallerani, E., Debiasi, M., …, & DeCensi, A. (2026). Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00841

Vancouver

Gandini S, Guerrieri-Gonzaga A, Serrano D, Rizzo R, Lazzeroni M, Puntoni M, et al. Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00841

BibTeX
@article{Gandini2026,
  author = {Gandini, Sara and Guerrieri-Gonzaga, Aliana and Serrano, Davide and Rizzo, Roberta and Lazzeroni, Matteo and Puntoni, Matteo and Buttiron Webber, Tania and Aurilio, Gaetano and Johansson, Harriet and Carbone, Alessio and Giordano, Livia and Digennaro, Maria and Cortesi, Laura and Millo, Francesco and Cagossi, Katia and Aprile, Giuseppe and Serra, Patrizia and Gallerani, Elisa and Debiasi, Marcio and Sousa, Berta and Gouveia, Pedro and Bonanni, Bernardo and DeCensi, Andrea},
  title = {Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-00841}
}
Kostenlos starten →